Hydroxychloroquine can impair tumor response to anti-PD1 in subcutaneous mouse models
Simon Wabitsch, John C. McVey, Chi Ma, Benjamin Ruf, Olena Kamenyeva, Justin McCallen, Laurence P. Diggs, Bernd Heinrich, Tim F. Greten
Abstract
T cells. This study shows that HCQ treatment can result in immunotherapy failure due to its immunosuppressive effects that offset both increased MHC-I expression by tumor cell and direct cytotoxicity.
Topics & Concepts
HydroxychloroquineIn vivoImmunotherapyCancer researchCD8MedicineImmunologyT cellCytotoxic T cellTumor necrosis factor alphaIn vitroTumor-infiltrating lymphocytesAntigenPharmacologyImmune systemChemistryInternal medicineBiologyDiseaseBiotechnologyInfectious disease (medical specialty)Coronavirus disease 2019 (COVID-19)BiochemistryCancer Immunotherapy and BiomarkersImmune Cell Function and InteractionImmune cells in cancer